{"id":"W2905465042","doi":"10.1182/blood-2018-99-114656","title":"Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD) Trial","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hamilton Health Sciences; McGill University Health Centre; Alberta Hospital Edmonton; London Health Sciences Centre; Juravinski Cancer Centre; Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; University of Calgary; Université de Montréal; Leukemia & Lymphoma Society of Canada; Université Laval; Queen Elizabeth II Health Sciences Centre; Hôpital Maisonneuve-Rosemont; Health Sciences Centre; CancerCare Manitoba; University of Alberta Hospital; Ottawa Hospital; University Health Network","funders":"","keywords":"Discontinuation; Medicine; Dasatinib; Internal medicine; Imatinib; Imatinib mesylate; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002942545,0.0009052631,0.001417536,0.0002035825,0.0003439449,0.00007939493,0.0004309801,0.0003354678,0.0007825187],"category_scores_gemma":[0.0003655179,0.0005742862,0.0003134411,0.0003552782,0.0002978754,0.0003953796,0.0001211464,0.0001513523,0.00001706771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008883472,"about_ca_system_score_gemma":0.0007525459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003200547,"about_ca_topic_score_gemma":0.001062317,"domain_scores_codex":[0.9959435,0.00009605992,0.001141126,0.001282033,0.0007522004,0.0007850104],"domain_scores_gemma":[0.9952801,0.0005264887,0.0008851963,0.002556599,0.0003264345,0.0004251976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4912011,0.03892949,0.2377072,0.002550853,0.0113881,0.0004423613,0.01976664,0.00001389184,0.1183479,0.0000783373,0.03074418,0.04882993],"study_design_scores_gemma":[0.6383502,0.05061036,0.008328629,0.002616112,0.004383578,0.0002114091,0.0007584859,0.0003048273,0.282615,0.0001428046,0.01060507,0.001073503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896239,0.0003584655,0.000221955,0.0007391971,0.0001593693,0.005660024,0.0007118026,0.0001896702,0.002335591],"genre_scores_gemma":[0.9716677,0.00005280467,0.0196332,0.00007753479,0.0009118431,0.001330816,0.001315209,0.0002142639,0.004796622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2293786,"threshold_uncertainty_score":0.9996709,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01882563202833285,"score_gpt":0.2718592563965646,"score_spread":0.2530336243682317,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}